Correction to: Novel sulphamoylated 2-methoxy estradiol derivatives inhibit breast cancer migration by disrupting microtubule turnover and organization
Authors:
Rustelle Janse van Vuuren, Mandie Botes, Tamarin Jurgens, Anna Margaretha Joubert, Iman van den Bout
Following publication of the original article [1], the authors notified us that the graph presented in Figure 3a is the same as Figure 2a in the published manuscript. Figure 3 below represents the true migration values achieved for cells blocked in interphase and treated with the different compounds.
Correction to: Novel sulphamoylated 2-methoxy estradiol derivatives inhibit breast cancer migration by disrupting microtubule turnover and organization
Authors
Rustelle Janse van Vuuren Mandie Botes Tamarin Jurgens Anna Margaretha Joubert Iman van den Bout
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.